Status:
COMPLETED
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
Lead Sponsor:
PATH
Conditions:
Encephalitis, Japanese B
Eligibility:
All Genders
20-36 years
Phase:
PHASE3
Brief Summary
The previously conducted JEV01 study looked at the immunogenicity and safety of the concurrent administration of Japanese Live Attenuated SA 14-14-2 and measles vaccines at the one month post vaccinat...
Detailed Description
Japanese encephalitis is the leading cause of viral neurological disease and disability in Asia. The severity of sequelae, together with the volume of cases, make JE the most important cause of viral ...
Eligibility Criteria
Inclusion
- Participant was enrolled in the JEV01 study previously conducted at RITM.
- Participant completed his/her vaccination schedule for the JEV01 study previously conducted at RITM.
- Participant's blood test results from JEV01 study indicate that he/she had seroconverted to measles vaccination.
- Participant's parents or legal guardian are/is willing to provide signed informed consent.
Exclusion
- Participant was withdrawn from the JEV01 study for any reason.
- Receipt of immune globulin or other blood products within 6 months of study (JEV02) entry or receipt of injected or oral corticosteroids or other immune modulator therapy (except routine vaccines) within 4 weeks of study (JEV02) entry.
- Any condition that in the opinion of the investigator, would interfere with the evaluation of the study objectives.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
519 Patients enrolled
Trial Details
Trial ID
NCT00412516
Start Date
December 1 2006
End Date
March 1 2010
Last Update
October 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute for Tropical Medicine (RITM)
Manila, Philippines